Australia will soon be joining the medical cannabis revolution. Its federal government has moved to legalize marijuana for medical and scientific purposes, and a Roy Morgan Research poll shows that 91 percent of Australians agree that medical marijuana should be legalized.
The poll, which was released on Monday, asked 644 Australians 14 years of age or older whether the use of marijuana for medical purposes should be made legal or not, with only 7 percent not voting in favor.
Roy Morgan Research CEO Michele Levine told The Guardian that she was not surprised to find the strongest support from those aged 50 and older, as “[t]his group is most susceptible to several of the conditions that medicinal marijuana can provide relief from: Parkinson’s disease, cancer, glaucoma and more.”
The poll results were released less than two weeks after Australia’s federal government announced plans to amend the Narcotic Drug Act 1967 to allow cannabis to be grown for medical and scientific purposes, without breaching international drug treaties.
“This Government is incredibly sympathetic to the suffering of those Australians with debilitating illnesses and we want to enable access to the most effective medical treatments available,” Health Minister Sussan Ley said in a statement.


Under current Australian laws, marijuana is classified as an illegal drug, and while penalties vary from state to state, the growth, use, possession or sale of it is punishable by a fine or jail time.
Even so, some Australian states are already taking steps toward medical marijuana research and development. For example, the New South Wales government just announced that it is committed to spending $9 million to support medical cannabis clinical trials for terminally ill adult cancer patients, making it the first Australian state to do so.
The government of Victoria is taking a slightly different route. It’s looking to legalize access to locally manufactured medical cannabis products for patients with exceptional circumstances and severe symptoms from 2017 onward.
While the individual states don’t have the authority to set rules for the cultivation of cannabis and production of medical marijuana products, the move by the federal government will make it easier.

Medical marijuana stocks

As it stands, there are only three medical marijuana companies listed on the ASX, and two of them are transformed mining companies. The three companies are as follows: MMJ Phytotech (ASX:MMJ), Erin Resources (ASX:ERI) and the most recent addition to the roster, Capital Mining (ASX:CMY).
MMJ Phytotech completed a $15.5-million merger with Canadian MMJ Bioscience in June to become the first ASX-listed medical marijuana company. The company has been working to accelerate its entry into the Australian medical cannabis market, completing a $2-million share placement and beginning a Phase 1 clinical trial of tetrahyrocannabidiol (THC) and cannabidiol (CDB) oral capsules for the treatment of pain and spasticity in multiple sclerosis patients following the federal government’s announcement.



Then there is Erin Resources, a gold explorer that completed a reverse takeover of Israel-based MGC Pharmaceuticals in August; MGC is a medical and cosmetic cannabis company that received two licenses in June to grow, process and trade its cannabis products in Europe.
Capital Mining, the third company, is currently in the process of entering the Australian medical marijuana market through the acquisition of a group of US and Canadian companies, including Denver-based Nutrawerx, Canadian Broken Coast Cannabis and Cannan Growersone.
Those interested in the medical cannabis space will no doubt be watching to see how legalization in Australia moves ahead and what other companies move into the ever-growing market moving forward.
 
Securities Disclosure: I, Kristen Moran, hold no direct investment interest in any company mentioned in this article.
Related reading: 
Legal Cannabis Stocks in North America
How to Invest in Medical Cannabis
Legalizing Medical Cannabis: A Look at the Laws Surrounding Medical Marijuana

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) announces it has completed a first closing of a non-brokered private placement of up to $2,000,000. The Company accepted subscriptions for 13,740,000 units at a price of $0.05 per unit, for gross proceeds of $687,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.075 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days

The Company paid $18,000 in cash and issued 160,000 warrants on the same terms as noted above to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until April 5, 2021. The Company is expecting to complete the financing by December 16, 2020. Proceeds will be used for working capital and to fund future investments.

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”), announces that further to its press release dated December 3, 2020, the TSX Venture Exchange has approved the repricing of 19,405,804 warrants of the Company that were originally issued on July 27, 2018, to $0.10. These warrants are set to expire on December 31, 2020.

For anybody wishing to exercise these Warrants, please contact the Chief Executive Officer, Terry Donnelly at the particulars below.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB) (TSX: ACB), and HEXO Corp. (NYSE: HEXO)

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has closed the 2nd and final tranche of its Unit financing. In connection with the closing, the Company issued 1,356,873 Units at a price of $0.55 per Unit, for gross proceeds of $746,280.15. Each Unit consists of one (1) common share and one (1) warrant. Each warrant entitles the holder to purchase one common share of the Company, at an exercise price of $0.75 per share, for a period of two years from the date of issuance. The warrants are subject to an acceleration right that allows the Company to give notice of an earlier expiry date if the Company’s share price on the CSE (or such other stock exchange the Company’s shares may be trading on) is equal to or greater than $1.25 for a period of 20 consecutive trading days. Finder’s fees of $42,542, 3,200 Finder’s shares and 80,550 Finder’s warrants were issued in connection with finder’s fees payable.

In total, the Company raised gross proceeds of $1,757,180 and issued 3,194,873 Units.

Keep reading... Show less

 Sweet Earth Holdings Corp. (CSE: SE) (FSE: 1KZ1) (OTCQB: SEHCF) (“Sweet Earth” the “Company”) is pleased to announce that it has received full Depository Trust Company (“DTC”) eligibility in the United States. On October 20, 2020, Sweet Earth announced that its shares had been listed on the United States’ Over-The-Counter Bulletin (“OTCQB”) under the ticker SEHCF.

DTC status means that Sweet Earth shares are now eligible to be transferred between brokerage accounts within the United States and significantly augments the ease in which American-based investors are able to trade Sweet Earth shares.

Keep reading... Show less